1. Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance


    Chenlong Yang et al, 2020, OncoTargets and Therapy CrossRef
  2. Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy
    N. L. Michmerhuizen et al, 2020, Journal of Neuro-Oncology CrossRef
  3. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas
    Daniela Jäger et al, 2017, Scientific Reports CrossRef
  4. Recent advances in understanding and managing chordomas
    Carl Youssef et al, 2016, F1000Research CrossRef
  5. Impact of silencing eEF2K expression on the malignant properties of chordoma
    Esra Aydemir et al, 2023, Molecular Biology Reports CrossRef
  6. Animal model considerations for chordoma research: reproducing the tumor microenvironment in vivo with humanized mice
    Beatrice Campilan et al, 2024, Frontiers in Oncology CrossRef
  7. In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
    Thibault Passeri et al, 2022, Frontiers in Oncology CrossRef
  8. From Notochord Formation to Hereditary Chordoma: The Many Roles ofBrachyury
    Yutaka Nibu et al, 2013, BioMed Research International CrossRef
  9. Molecular features and vulnerabilities of recurrent chordomas
    Carolin Seeling et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef